Contraindications to Exposure Therapy: Risks and Cautions

Can exposure therapy make anxiety worse?

The short answer is yes, transiently, and that rise belongs to the procedure rather than working against it. Exposure does not set out to keep the patient comfortable while approaching what they have spent years avoiding. It sets out to produce first-hand evidence that the thing they predict does not in fact happen. Arousal climbs before it settles, and that climb is the material the clinician works with.

The model that explains that work today is inhibitory learning and inhibitory retrieval, set out by Craske (2014) and updated by the same group in 2022. Extinction does not erase the original fear association: it builds a competing association alongside it, and what decides the outcome is whether the patient can retrieve that competitor when the stimulus turns up again. The active ingredient is therefore expectancy violation, the distance between what the patient anticipates and what actually occurs. For decades the technique was explained by habituation. Habituation is still an observable phenomenon inside the session, but the within-session fall in distress is a poor predictor of the medium-term result.

A transient worsening is recognised by its trajectory. Distress runs high during the exposure and through the hours that follow, and the patient is back at their previous level before the next appointment. Daily life does not narrow; more often it widens, because approaches appear that did not exist before. That is the expected pattern, and the clinician flags it when the treatment plan is presented.

Sustained deterioration, which is clinical deterioration proper, traces a different curve. Avoidance spreads to situations the patient tolerated before treatment began, sleep breaks for several nights in a row, the substance use that damps arousal returns, or thoughts of death gain ground. The contraindications to exposure therapy exist precisely to tell apart, in advance, the patient whose distress will pass from the patient in whom it may settle.

What are the contraindications to exposure therapy?

The contraindications to exposure therapy fall on two planes that are best kept apart. An absolute contraindication says the technique does not apply now, with this patient, in this state. A relative contraindication says it applies with cautions, a different sequence and a more conservative calibration of the challenge.

One note first, because the confusion is constant: this is not the equipment chapter. The contraindications of the virtual reality headset itself, such as photosensitive epilepsy or an active vestibular disorder, belong to the device and are settled in a screening of their own. What follows concerns exposure as a technique, whether it is practised in imagination, in vivo or inside a virtual environment.

• Active suicidal risk, with structured ideation, a plan or intent. The priority is the patient's safety and the management of that risk, not an approach to the feared stimulus.
• Active psychosis or recent decompensation. Exposure needs stable reality testing for an expectancy violation to mean anything at all.
• Active substance use with unstabilised dependence. Use operates as an escape behaviour and blocks the learning the procedure is after.
• Relevant medical instability, where the doctor in charge advises against intense and sustained autonomic arousal.
• Cognitive impairment that prevents the patient from understanding the task, holding the instruction in mind or reporting what is being felt.
• A real and current threat in the patient's environment. Where violence is ongoing the fear is not out of proportion: it is useful information, and the intervention runs through protection.

The word absolute misleads. In routine practice almost none of these contraindications to exposure therapy describes a patient for good; each one describes a moment. Suicidal risk is managed, substance use is stabilised, a psychotic episode remits. The decision is about order and sequence, not a verdict on the person.

Order matters in the other direction too. Once the picture has stabilised, a gradable environment allows a first rung that would be unworkable in the street: the agoraphobia exposure scenario opens on a nearly empty square and adds crowd density step by step, with the clinician deciding each increment.

Is exposure therapy suitable for everyone?

No, and the honest answer is that no psychological technique is. Outside the block of contraindications to exposure therapy lies a far more populated band: patients for whom the technique is indicated, but who need explicit clinical cautions and a sequence other than the usual one.

NICE CG113 places exposure as a component of cognitive behavioural treatment rather than a standalone intervention. That framing settles much of the doubt about indication: where the patient's profile calls first for regulation, behavioural activation or work on substance use, exposure is not discarded, it is ordered later.

• Severe depression with marked behavioural inhibition. Behavioural activation usually comes before any approach work.
• Prominent dissociative symptoms in post-traumatic stress. The ISTSS 2018 guidelines recommend prior stabilisation and careful handling of work with the traumatic memory.
• Medical comorbidity that limits arousal or travel, with a report from the doctor in charge on the table.
• A fragile alliance or a badly calibrated expectation, where the patient expects the fear to disappear without going anywhere near it.
• A family context that sustains avoidance and neutralises between sessions whatever ground was gained.
• A comprehension barrier: language, developmental level or difficulty putting into words what is being anticipated.

DSM-5-TR contributes here only what belongs to it: the criteria that delimit a specific phobia or a post-traumatic stress presentation. It serves to keep the clinician from treating as a phobia something that is another thing altogether, whether a delusion, a proportionate reaction to a real threat or a poorly explored medical problem. It does not serve to attach labels to whoever happens to be reading an article.

The practical reading is straightforward. The contraindications to exposure therapy are settled with a not for now; clinical cautions are settled with a yes, under these written conditions. Blurring the two produces the two symmetrical errors: excluding the patient who would benefit, and exposing the patient who is not yet in a position for it.

What does the screening before a first exposure cover?

The screening that rules out contraindications to exposure therapy is not a symptom questionnaire. It is four questions the clinician answers for themselves, with the clinical record open, before the technique is put to the patient at all.

• Is there safety? Suicidal risk, self-harm, threat in the environment, substance use with which the patient damps arousal.
• Is there enough stability? Sleep, medication, psychotic or dissociative episodes, medical and life circumstances over recent months.
• Is there comprehension and consent? The patient understands that distress will rise, knows why it rises, and accepts that working contract.
• Are the working conditions there? A sustainable frequency, support between sessions, the option of repeating the approach in more than one context.

None of the four is answered by impression. They are answered with data from the interview, with whatever reports are available and, where there is drug treatment or medical pathology, with a call to the professional carrying the case. The practice readiness checklist for virtual reality work gathers this clinical screening alongside the equipment one, so that neither of the two gets taken for granted.

The screening repeats. The contraindications to exposure therapy are not a first-appointment formality: suicidal risk can surface in the sixth session and substance use can return without warning. Safety status is therefore reviewed every time the plan is reviewed, not once at the outset.

What risks appear when exposure is poorly indicated?

The risks of exposure are not distributed at random when the indication is wrong, and the most frequent of them is not spectacular harm. It is dropout. A patient offered an approach they cannot sustain rarely argues about the plan: they stop coming, and often stop asking for help for years.

The available work on tolerance and dropout in exposure treatment suggests that the acceptability of a treatment is decided in the first few appointments. Contraindications to exposure therapy that went unexplored are paid for exactly there, in the stretch where the patient is still working out whether any of this is of use to them.

There is a second risk, quieter than the first: reinforcing avoidance. If the approach is pitched above what the patient can sustain and ends in escape, the experience confirms the feared prediction instead of disconfirming it. The stopping criterion inside a session deserves separate treatment; here it is enough to note that a badly fitted indication puts that criterion in play from the first minute.

The third risk is one of opportunity. Every week spent exposing a patient who needed stabilisation first is a week not spent on the problem holding the presentation in place. And there is a fourth risk, characteristic of these years: exposure attempted on the patient's own account with downloaded material, with no clinician in charge to adjust the progression or to collect what happens afterwards. In that scenario the contraindications to exposure therapy are simply invisible.

How are contraindications to exposure therapy documented?

What is not written down does not exist once another professional reviews the case. The contraindications to exposure therapy are documented like any other clinical decision: what was explored, what was found, what was decided and on what date.

Three entries usually cover it. The first is the conclusion of the screening and the data supporting it. The second is the set of cautions agreed when the indication goes ahead with conditions: smaller rungs, shorter sessions, a review of substance use, coordination with the psychiatrist seeing the patient. The third is the review date, because a not for now with no date on it drifts by inertia into a not ever.

Informed consent covers the part that belongs to the patient: that distress will rise during the procedure, what will be done if something unforeseen appears, and what alternatives exist where exposure does not apply. Where the conclusion is that it does not apply in this practice, the referral forms part of the closure: a colleague working within a different frame, the local mental health service, or whichever route the referral network with GPs and psychiatrists already has in place.

Documenting this chapter well carries an advantage that is rarely discussed. Contraindications to exposure therapy set down in writing order the conversation with the patient and protect the clinician's position: when the plan changes there is a record of why it changed, rather than an impression reconstructed months later.

How does all this translate into everyday practice?

None of these decisions calls for a lengthy procedure. It calls for an order: safety first, then stability, then comprehension and working conditions, and only then a first exposure. The contraindications to exposure therapy are the part of the plan that gets settled before the patient faces anything at all.

The record is what holds that order together when the diary is full. A system that stores the state of the screening, the cautions agreed and the review date next to the session they belong to keeps the clinical decision from living only in the professional's memory.

For teams weighing up virtual reality exposure, booking a demonstration of the system shows how a hierarchy is configured, where the decision about indication is recorded and how each patient's cautions are documented. Current plans run at $119 a month for Starter, $289 for Clinic and $1,499 for Enterprise, with a 30-day refund window, and the detail sits on the plans and pricing page. The clinical decision stays with the licensed clinician carrying the case; the tool only keeps a record of it.

This article is for informational purposes for psychology professionals. It is not clinical advice for any individual case and does not replace the judgment of the licensed psychologist in charge. VRET is professional clinical-support software, not a CE-marked medical device.